Protagenic Therapeutics Warrant
PTIXW
PTIXW was delisted on the 2nd of January, 2026.
2 hedge funds and large institutions have $78K invested in Protagenic Therapeutics Warrant in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 0 closing their positions.
100% more funds holding
Funds holding: 1 → 2 (+1)
13% more capital invested
Capital invested by funds: $69K → $78K (+$9K)
1.07% more ownership
Funds ownership: 1.07% → 2.14% (+1.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$48.3K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$29 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WAM
1
Warberg Asset Management
Winnetka,
Illinois
| $78K | +$48.3K | +180,532 | +99% |
|
|
2
UBS Group
Zurich,
Switzerland
| – | +$29 | +108 | New |
|
PTIXW Hedge Fund Activity: Q1 2022 in Review
2 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Protagenic Therapeutics Warrant (PTIXW) for Q1 2022, worth a combined $78K — up 13% from $69K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new PTIXW positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Warberg Asset Management, adding an estimated $48.3K.
- 2 institutional investors held Protagenic Therapeutics Warrant (PTIXW) as of Q1 2022, up from 1 in Q4 2021.
- Funds reported $78K of Protagenic Therapeutics Warrant stock for Q1 2022, up 13% quarter-over-quarter.
- 1 fund opened new Protagenic Therapeutics Warrant positions in Q1 2022 and 0 closed out, a net change of +1 holder.
- The largest Protagenic Therapeutics Warrant buyer in Q1 2022 was Warberg Asset Management, an estimated $48.3K added.
Based on aggregated 13F filings for Q1 2022.